Analysts Chime in on Corning, Quest Diagnostics, Canadian Pacific, Norfolk Southern, and More

Although it’s FOMC day, the markets are rather quiet as all three major index futures are modestly in the red. In this article, we take a look at how analysts have recently weighed in on Corning Incorporated (NYSE:GLW), Quest Diagnostics Inc (NYSE:DGX), Canadian Pacific Railway Limited (USA) (NYSE:CP), CSX Corporation (NASDAQ:CSX), and Norfolk Southern Corp. (NYSE:NSC).

We will also take a look at how elite funds are positioned among the five stocks.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

matthew siddons / Shutterstock.com

Corning Incorporated (NYSE:GLW) is 2% in the red after Goldman analyst Doug Clark changed his rating to ‘Neutral’ from ‘Buy’, citing valuation reasons for the downgrade. Corning has rallied around a third since Clark’s original upgrade in April of last year. The investment bank has a $29 price target. Of the 742 elite funds we track, 41 funds owned $614.28 million of Corning Incorporated (NYSE:GLW) and accounted for 2.70% of the float on December 31, versus 36 funds and $662 million respectively on September 30.

While Goldman might have downgraded Corning, the investment bank upgraded Quest Diagnostics Inc (NYSE:DGX), with analyst Isaac Ro upgrading the stock to ‘Conviction Buy’ from ‘Buy’ and setting a price target of $113 per share. That’s up from the previous $101 per share. Ro believes Quest will be a beneficiary of future changes in the healthcare system as costs move more to the individual from intermediaries. Not surprisingly, Quest Diagnostics Inc (NYSE:DGX) shares are in the green this morning as the market factors in the upgrade. According to our data, 28 top funds had a bullish position in Quest Diagnostics Inc (NYSE:DGX) at the end of December, up 4 funds from the previous quarter. Cliff Asness’ AQR Capital Management owned more than 1.26 million shares at the end of the fourth quarter.

On the next page, we put the analyst commentary surrounding Canadian Pacific Railway Limited (USA), CSX Corporation, and Norfolk Southern Corp under the microscope.